171 related articles for article (PubMed ID: 18550029)
1. MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands.
Lui K; Tamura T; Mori T; Zhou D; Chen S
Biochem Pharmacol; 2008 Jul; 76(2):208-15. PubMed ID: 18550029
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
3. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S
Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674
[TBL] [Abstract][Full Text] [Related]
4. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists.
Wilson VS; Bobseine K; Gray LE
Toxicol Sci; 2004 Sep; 81(1):69-77. PubMed ID: 15166400
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
[TBL] [Abstract][Full Text] [Related]
7. Role of estrogen receptor ligand and estrogen response element sequence on interaction with chicken ovalbumin upstream promoter transcription factor (COUP-TF).
Klinge CM
J Steroid Biochem Mol Biol; 1999 Nov; 71(1-2):1-19. PubMed ID: 10619353
[TBL] [Abstract][Full Text] [Related]
8. The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Lu Q; Yue W; Wang J; Liu Y; Long B; Brodie A
Breast Cancer Res Treat; 1998 Jul; 50(1):63-71. PubMed ID: 9802621
[TBL] [Abstract][Full Text] [Related]
9. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
10. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
11. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Long BJ; Tilghman SL; Yue W; Thiantanawat A; Grigoryev DN; Brodie AM
J Steroid Biochem Mol Biol; 1998 Nov; 67(4):293-304. PubMed ID: 9883986
[TBL] [Abstract][Full Text] [Related]
12. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
[TBL] [Abstract][Full Text] [Related]
13. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta.
Escande A; Pillon A; Servant N; Cravedi JP; Larrea F; Muhn P; Nicolas JC; Cavaillès V; Balaguer P
Biochem Pharmacol; 2006 May; 71(10):1459-69. PubMed ID: 16554039
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen agonism and estrogen antagonism of c-fos gene promoter activity through non-consensus-responsive elements in MC3T3-E1 osteoblasts.
Ishibashi O; Yamagishi T; Hanada K; Kawashima H
Biochem Biophys Res Commun; 2001 Dec; 289(3):705-11. PubMed ID: 11726205
[TBL] [Abstract][Full Text] [Related]
16. Identification of estrogen receptor beta expression in Chinese hamster ovary (CHO) cells and comparison of estrogen-responsive gene transcription in cells adapted to serum-free media.
Thomas PB; Risinger KE; Klinge CM
J Steroid Biochem Mol Biol; 2003 Jul; 86(1):41-55. PubMed ID: 12943744
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
18. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Jensen J; Kitlen JW; Briand P; Labrie F; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2003 Mar; 84(4):469-78. PubMed ID: 12732292
[TBL] [Abstract][Full Text] [Related]
19. Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1.
Li Y; Birnbaumer L; Teng CT
Mol Endocrinol; 2010 May; 24(5):969-80. PubMed ID: 20211987
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors and their antitumor effects in model systems.
Brodie A; Lu Q; Liu Y; Long B
Endocr Relat Cancer; 1999 Jun; 6(2):205-10. PubMed ID: 10731110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
